Oncology Research Unit
Mèxico DF, Mexico City, 06725, Mexico
Completed
NCT Number: NCT01230008
Radiotherapy in Primary Mediastinal Lymphoma
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of primary mediastinal lymphoma No previous treatment performance status < 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function
Exclusion criteria
pregnancy
-
Treatment and study plan
no drugs
RadiationAdjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
Other names: no applicable
Primary outcomes
-
measurement of progression free-survival and overall survival at > 5 years
Time frame: 5 years
Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP
Secondary outcomes
-
assess toxicity secondary to mediastinal radiotherapy
Time frame: > 5 years
Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity
Sponsors and collaborators
Lead sponsor
Instituto Mexicano del Seguro Social
Other Gov
Registry information
Official study title
Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP
Acronym: pml
Important dates
- Study start
- 2002
- Primary completion
- 2007
- Study completion
- 2009
- First posted
- Oct 28, 2010
- Registry last updated
- Oct 28, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.